Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Eisai

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Eisai's 2012 sales performance.

Eisai Co., Ltd.

Biogen to acquire Reata for approximately $7.3bn

Biogen to acquire Reata for approximately $7.3bn

The deal comes just a few weeks after Biogen and Eisai’s jointly developed Alzheimer’s disease drug was granted traditional approval in the US for use in patients with mild

Biogen/Eisai’s Alzheimer’s disease drug shows promise as a subcutaneous formulation

Biogen/Eisai’s Alzheimer’s disease drug shows promise as a subcutaneous formulation Biogen and Eisai’s Alzheimer’s disease drug has shown promise as a subcutaneous (SC) formulation, according to new data presented by Eisai at this year’s Alzheimer’s Association International

BMS obtains global rights to Prothena’s Alzheimer’s drug in deal worth $2.2bn

BMS obtains global rights to Prothena’s Alzheimer’s drug in deal worth $2.2bn Earlier this month, Biogen and Eisai’s Alzheimer’s disease drug Leqembi was granted traditional approval by the US Food and Drug Administration, making it the first and only approved

Biogen/Eisai’s Alzheimer’s disease drug granted full FDA approval

Biogen/Eisai’s Alzheimer’s disease drug granted full FDA approval In a very welcome move, Biogen and Eisai’s Alzheimer’s disease drug has been granted traditional approval by the US Food and Drug Administration (FDA). ... Eisai’s supplemental biologics application for approval under the traditional pathway was

Biogen/Eisai’s Alzheimer’s drug backed by FDA advisory committee for traditional approval

Biogen/Eisai’s Alzheimer’s drug backed by FDA advisory committee for traditional approval Biogen and Eisai’s Alzheimer’s disease drug has been recommended for traditional approval by a US Food and Drug Administration (FDA) panel of experts. ... Eisai’s supplemental biologics application for approval under the traditional pathway is

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

The importance of accelerating clinical trial diversity
Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
Digital Opinion Leaders: The Role of Influencers in Medical Communications
There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
Creating Hope Though Action – World Suicide Prevention Day
At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....